ATE312354T1 - Diagnose von alzheimerkrankheit unter verwendung von ldl-rezeptor-protein-1 - Google Patents

Diagnose von alzheimerkrankheit unter verwendung von ldl-rezeptor-protein-1

Info

Publication number
ATE312354T1
ATE312354T1 AT01939264T AT01939264T ATE312354T1 AT E312354 T1 ATE312354 T1 AT E312354T1 AT 01939264 T AT01939264 T AT 01939264T AT 01939264 T AT01939264 T AT 01939264T AT E312354 T1 ATE312354 T1 AT E312354T1
Authority
AT
Austria
Prior art keywords
disease
alzheimer
brain
diagnosis
receptor protein
Prior art date
Application number
AT01939264T
Other languages
English (en)
Inventor
Berislav V Zlokovic
Original Assignee
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southern California filed Critical Univ Southern California
Application granted granted Critical
Publication of ATE312354T1 publication Critical patent/ATE312354T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
AT01939264T 2000-05-23 2001-05-23 Diagnose von alzheimerkrankheit unter verwendung von ldl-rezeptor-protein-1 ATE312354T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20642800P 2000-05-23 2000-05-23
US24626800P 2000-11-06 2000-11-06
PCT/US2001/016561 WO2001090758A2 (en) 2000-05-23 2001-05-23 Diagnosis of alzheimer's disease ldl receptor protein-1

Publications (1)

Publication Number Publication Date
ATE312354T1 true ATE312354T1 (de) 2005-12-15

Family

ID=26901346

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01939264T ATE312354T1 (de) 2000-05-23 2001-05-23 Diagnose von alzheimerkrankheit unter verwendung von ldl-rezeptor-protein-1

Country Status (8)

Country Link
US (2) US7695903B2 (de)
EP (1) EP1290451B1 (de)
JP (1) JP4851676B2 (de)
AT (1) ATE312354T1 (de)
AU (1) AU2001264801A1 (de)
CA (1) CA2408566A1 (de)
DE (1) DE60115638T2 (de)
WO (1) WO2001090758A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
ATE312354T1 (de) * 2000-05-23 2005-12-15 Univ Southern California Diagnose von alzheimerkrankheit unter verwendung von ldl-rezeptor-protein-1
DK1372708T3 (da) 2001-02-13 2008-10-20 Us Gov Sec Army Vaccine til transkutan immunisering mod rejsediarre
WO2004001421A2 (en) * 2002-06-21 2003-12-31 Innogenetics N.V. Method for the diagnosis and differential diagnosis of neurological diseases
US7608586B2 (en) * 2003-06-11 2009-10-27 The University Of Rochester Soluble low-density lipoprotein receptor related protein binds directly to Alzheimer's amyloid-beta peptide
ES2332846B1 (es) 2007-10-26 2010-07-08 Grifols, S.A. Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos.
US8946165B2 (en) * 2008-09-29 2015-02-03 The Regents Of The University Of California Compounds for reversing and inhibiting protein aggregation, and methods for making and using them
CA2777752A1 (en) * 2009-10-17 2011-04-21 Zz Alztech L.L.C. Mutant low-density lipoprotein receptor related protein with increased binding to alzheimer amyloid-beta peptide
US20220113320A1 (en) * 2019-01-10 2022-04-14 Fundación Biomédica Galicia Sur (Fbgs) In vitro method for the diagnosis or prognosis of neurodegenerative disorders
CN110192859B (zh) * 2019-05-05 2020-05-19 兰月 一种磁共振测量人脑类淋巴通路清除效率的方法
KR102549828B1 (ko) * 2021-03-22 2023-07-04 경희대학교 산학협력단 Bbb-온-칩

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4758583A (en) 1984-03-19 1988-07-19 The Rockefeller University Method and agents for inhibiting protein aging
US5766856A (en) 1984-03-19 1998-06-16 The Picower Institute For Medical Research Diagnostic method for evaluating advanced glycosylation endproducts using MAC-2 receptor
US5202424A (en) 1984-03-19 1993-04-13 The Rockefeller University Mesangial cell-derived receptors for advanced glycosylation endproducts and uses thereof
US4900747A (en) 1984-03-19 1990-02-13 The Rockefeller University Method and agents for removing advanced glycosylation endproducts
DE69321893T2 (de) * 1992-07-22 1999-05-12 Mclean Hospital Corp Verfahren zum Nachweis von Alzheimer-Krankheit
US6410598B1 (en) 1994-02-03 2002-06-25 Michael P. Vitek Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
US5962245A (en) 1995-04-05 1999-10-05 The Picower Institute For Medical Research Methods for detecting the presence of advanced glycosylation endproducts
CA2246561A1 (en) * 1995-07-27 1997-02-13 The American National Red Cross Modulators of expression and function of lrp in alzheimer's disease
US6156311A (en) 1995-07-27 2000-12-05 The American National Red Cross Modulators of expression and function of LRP in alzheimer's disease
US5864018A (en) 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
US6472140B1 (en) 1997-09-05 2002-10-29 The General Hospital Corporation α-2- macroglobulin therapies and drug screening methods for Alzheimer's disease.
US6413512B1 (en) 1998-02-13 2002-07-02 National Enzyme Company Composition and method for treating disease by increasing activated α2 macroglobulin in the blood and extravascular tissue
ATE312354T1 (de) * 2000-05-23 2005-12-15 Univ Southern California Diagnose von alzheimerkrankheit unter verwendung von ldl-rezeptor-protein-1
US6825164B1 (en) 2000-08-14 2004-11-30 The Trustees Of Columbia University In The City Of New York Method to increase cerebral blood flow in amyloid angiopathy
WO2002057496A2 (en) * 2001-01-18 2002-07-25 Socratech L.L.C. Gene expression profiling of endothelium in alzheimer's disease
EP1532258A4 (de) * 2002-06-11 2006-11-02 Socratech L L C Behandlung einer vaskulären funktionsstörung und von morbus alzheimer

Also Published As

Publication number Publication date
JP4851676B2 (ja) 2012-01-11
CA2408566A1 (en) 2001-11-29
DE60115638D1 (de) 2006-01-12
US20040259159A1 (en) 2004-12-23
DE60115638T2 (de) 2006-08-17
JP2004510957A (ja) 2004-04-08
WO2001090758A2 (en) 2001-11-29
US7695903B2 (en) 2010-04-13
EP1290451B1 (de) 2005-12-07
AU2001264801A1 (en) 2001-12-03
US20050239062A1 (en) 2005-10-27
WO2001090758A3 (en) 2002-08-29
EP1290451A2 (de) 2003-03-12

Similar Documents

Publication Publication Date Title
ATE312354T1 (de) Diagnose von alzheimerkrankheit unter verwendung von ldl-rezeptor-protein-1
BG104075A (en) Combined treatment including atorvastatin and an antihypertonic form
IS6170A (is) Efni til öftrunar og meðferðar mýlildis
ATE300306T1 (de) Pharmazeutische zusammensetzung zur ophtalmologischen und rhinologischen anwendung
ATE298233T1 (de) Kosmetische und pharmazeutische öl-in-wasser- emulsionen von polyethermodifizierten polysiloxanen
MA29273B1 (fr) Combinaison synergique de xolair/omalizumab/e25 et d'un agent immunosuppresseur
Powell et al. Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A
JP2020152738A (ja) 抗発作治療のためのａ１９−１４４、ａ２−７３およびある特定の抗コリンエステラーゼ阻害剤、組成物および方法
SE9704644D0 (sv) New use
Adler et al. Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder.
NO20055392L (no) Behandling av tilstander som omfatter amyloide plaque
BRPI0404050A (pt) Uso de um composto ou de um seu sal ou éster farmaceuticamente aceitável, formulação farmacêutica, formulação acondicionada, composto, e, método para prevenir e/ou tratar hiperplasia benigna da próstata em pacientes em necessidade de tal prevenção ou tratamento
Messerli et al. Diabetes, hypertension, and cardiovascular disease: An update
Kocsis et al. Pharmacotherapy for ‘pure’dysthymia: setraline vs. imipramine and placebo
Mannucci Desmopressin (DDAVP) and factor VIII: the tale as viewed from Milan (and Malmö)
Caminiti et al. Effects of ivabradine in patients with copd and non-paroxysmal atrial fibrillation: a pilot study
DE50005282D1 (de) Medikament sowie aufeinander abgestimmte kombination von medikamenten
Bruning et al. Ectopic adrenocortical tissue along the spermatic cord
Chobanian Current Use of Diuretics in the Management of Hypertension
Nicot et al. Intravenous amiodarone-induced acute liver failure in cardiac surgery intensive care unit
Raal Dyslipidaemia–getting to lower LDL targets safely
Liendo-Martínez et al. Differences in the Evolution of Lung Function Before and After Treatment With Antifibrotics in Patients With Interstitial Lung Disease
Mahavadi Autophagy in Amiodarone induced Lung Fibrosis: A Close Look
Gupta et al. Carotid Stenosis with Thrombus
Briget da Graca et al. Preoperative β-Blockers for Isolated Coronary Artery Bypass Graft

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties